港股18A首例反向收购案有了进展。日前,嘉和生物-B(06998.HK)向港交所递交上市申请书,亿腾医药通过换股方式反向收购嘉和生物,合并后公司将更名为亿腾嘉和医药集团有限公司(下称“亿腾嘉和”)。这是港股首起18A未盈利生物科技公司反向并购案例。按照计划,嘉和生物将向亿腾医药股东发行发行新股作为对价,每股理论发行价格2.96港元,较嘉和生物4月7日收盘价溢价66.22%。在此次交易中,亿腾医药、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.